{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:00:26Z","timestamp":1794718826534,"version":"4.9.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The optimal busulfan exposure window in pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) remains to be defined. We identify this window for patients receiving busulfan within the prospective international, randomized controlled phase 3 ALLSCTped 2012 FORUM trial. We included 145 participants receiving fludarabine-busulfan-thiotepa conditioning, with available busulfan plasma levels. Busulfan exposure was estimated using a validated pediatric population pharmacokinetic model. Primary outcomes were event-free survival (EFS) and graft-versus-host disease-free relapse-free survival (GRFS). Patients were aged between 0.5 and 19.5 years, with a median follow-up of 5.0 years. The optimal busulfan exposure was defined as area under busulfan concentration curve (cAUC) of 73.3 to 98.0 mg.h\/L based on EFS and GRFS. Patients with nonoptimal exposure had lower EFS (hazard ratio [HR], 1.93; p = 0.008) and GRFS (HR, 2.01; p = 0.002). Underexposure (cAUC &amp;lt;73.3 mg.h\/L) was associated with higher relapse rates (HR, 1.93; p = 0.019), and overexposure (cAUC &amp;gt;98.0 mg.h\/L) with an increased risk of treatment-related toxicities and graft-versus-host disease. Patients with optimal busulfan exposure showed no differences in EFS, GRFS, overall survival, or relapse with post hoc matched total-body irradiation (TBI) recipients (n = 51 in each group). This study identifies a favorable busulfan exposure window for pediatric patients with ALL undergoing HSCT from an HLA-matched donor. Therapeutic drug monitoring for optimized personalized busulfan dosing improves HSCT outcomes and might be validated for use as an alternative to irradiation. This trial was registered at EudraCT as 2012-003032-22 and on www.ClinicalTrials.gov as NCT01949129.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019142","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:53:55Z","timestamp":1772657635000},"page":"3719-3730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-8377","authenticated-orcid":false,"given":"Khalil","family":"Ben Hassine","sequence":"first","affiliation":[{"name":"1Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-0479","authenticated-orcid":false,"given":"Yvonne","family":"Gloor","sequence":"additional","affiliation":[{"name":"2CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-6963","authenticated-orcid":false,"given":"Isabelle","family":"Dupanloup","sequence":"additional","affiliation":[{"name":"2CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-7049","authenticated-orcid":false,"given":"Chakradhara Rao Satyanarayana","family":"Uppugunduri","sequence":"additional","affiliation":[{"name":"2CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland"},{"name":"3Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5592","authenticated-orcid":false,"given":"Vid","family":"Mlakar","sequence":"additional","affiliation":[{"name":"2CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5883-391X","authenticated-orcid":false,"given":"Fanny","family":"Gonzales","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-1186","authenticated-orcid":false,"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"4Division of Stem Cell Transplantation, University Children's Hospital of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-1935","authenticated-orcid":false,"given":"Marianne","family":"Ifversen","sequence":"additional","affiliation":[{"name":"5Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-4482","authenticated-orcid":false,"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"6The Children`s Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-4501","authenticated-orcid":false,"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-7961","authenticated-orcid":false,"given":"Tony H.","family":"Truong","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Oncology and Cellular Therapy, Alberta Children\u2019s Hospital, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"9Hematology-Oncology Division, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lochie","family":"Teague","sequence":"additional","affiliation":[{"name":"10Starship Blood and Cancer Center, Starship Children's Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-0651","authenticated-orcid":false,"given":"Jacek","family":"Toporski","sequence":"additional","affiliation":[{"name":"11Center of Allogeneic Stem Cell Transplantation and Cellular Therapy (CAST), Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2886","authenticated-orcid":false,"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"12Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-7082","authenticated-orcid":false,"given":"Ulrike","family":"Poetschger","sequence":"additional","affiliation":[{"name":"13St. Anna Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-7031","authenticated-orcid":false,"given":"Maja","family":"Krajinovic","sequence":"additional","affiliation":[{"name":"14Centre Hospitalier Universitaire Sainte Justine Research Center Azrieli, Departments of Pediatrics and Pharmacology\/Physiology, University of Montreal, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Ka\u0142wak","sequence":"additional","affiliation":[{"name":"15Department of Pediatric Hematology\/Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"16Pediatric Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy"},{"name":"17School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-2664","authenticated-orcid":false,"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[{"name":"18Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Ges\u00f9, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"additional","affiliation":[{"name":"19Division for Stem Cell Transplantation and Immunology, Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"Christina","family":"Peters","sequence":"additional","affiliation":[{"name":"20Department of Pediatrics and Adolescent Medicine, St. Anna Children\u2019s Hospital, St. Anna Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-0793","authenticated-orcid":false,"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[{"name":"21Hemato-Immunology Department, Robert Debr\u00e9 Hospital, Groupe hospitalo-universitaire de l'Assistance publique - H\u00f4pitaux de Paris Nord Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-6498","authenticated-orcid":false,"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, Geneva University Hospitals, Geneva, Switzerland"},{"name":"2CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"4","key":"2026052611213877700_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026052611213877700_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41409-020-0854-0","article-title":"Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? a multicenter EBMT-PDWP study","volume":"55","author":"Willasch","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026052611213877700_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/bloodadvances.2023010591","article-title":"Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026052611213877700_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.20.03261","article-title":"Continued role for radiation in the conditioning regimen for children with ALL","volume":"39","author":"Pulsipher","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052611213877700_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/bloodadvances.2024014548","article-title":"Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM","volume":"9","author":"Kalwak","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026052611213877700_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11912-018-0719-5","article-title":"Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia","volume":"20","author":"Lawitschka","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2026052611213877700_bib7","doi-asserted-by":"crossref","first-page":"775485","DOI":"10.3389\/fped.2021.775485","article-title":"Total body irradiation forever? Optimising chemotherapeutic options for irradiation-free conditioning for paediatric acute lymphoblastic leukaemia","volume":"9","author":"Ben Hassine","year":"2021","journal-title":"Front Pediatr"},{"issue":"11","key":"2026052611213877700_bib8","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","article-title":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial","volume":"36","author":"Eichinger","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026052611213877700_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","article-title":"Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients","volume":"60","author":"Lawson","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026052611213877700_bib10","doi-asserted-by":"crossref","first-page":"826004","DOI":"10.3389\/fphar.2022.826004","article-title":"Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; where do we stand?","volume":"13","author":"van der Stoep","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026052611213877700_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17425255.2023.2192924","article-title":"Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions","volume":"19","author":"Combarel","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"2026052611213877700_bib12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","article-title":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Domingos","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026052611213877700_bib13","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"19","key":"2026052611213877700_bib14","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bognar","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026052611213877700_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28079","article-title":"The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"67","author":"Friend","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026052611213877700_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2021005224","article-title":"Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen","volume":"6","author":"Versluijs","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026052611213877700_bib17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","article-title":"I.V. busulfan in pediatrics: a novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients","volume":"33","author":"Nguyen","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"2026052611213877700_bib18","unstructured":"European Medicines Agency\n          . Busulfan Fresenius-Kabi product information. 2021. European Medecines Agency, Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/busulfan-fresenius-kabiPublisher."},{"issue":"1","key":"2026052611213877700_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0000000000000468","article-title":"Therapeutic drug monitoring of busulfan for the management of pediatric patients: cross-validation of methods and long-term performance","volume":"40","author":"Choong","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"9","key":"2026052611213877700_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/psp4.12683","article-title":"Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study","volume":"10","author":"Ben Hassine","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"2026052611213877700_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/FTD.0000000000001217","article-title":"Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients","volume":"46","author":"Ben Hassine","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"9","key":"2026052611213877700_bib22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.bbmt.2019.05.021","article-title":"Harmonization of Busulfan Plasma Exposure Unit (BPEU): a community-initiated consensus statement","volume":"25","author":"McCune","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026052611213877700_bib23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026052611213877700_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12874-019-0738-4","article-title":"A novel approach to determine two optimal cut-points of a continuous predictor with a U-shaped relationship to hazard ratio in survival data: simulation and application","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"suppl 1","key":"2026052611213877700_bib25","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2024-198741","article-title":"Total body irradiation versus chemotherapy conditioning before allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia patients aged 2 to 4 years: a retrospective study of the EBMT Pediatric Diseases Working Party","volume":"144","author":"Eichinger","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026052611213877700_bib26","first-page":"2854","article-title":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","volume":"109","author":"Oostenbrink","year":"2024","journal-title":"haematologica"},{"issue":"2","key":"2026052611213877700_bib27","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026052611213877700_bib28","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026052611213877700_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of Thymoglobulin((R)) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2026052611213877700_bib30","doi-asserted-by":"crossref","first-page":"828094","DOI":"10.3389\/fphar.2022.828094","article-title":"Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept","volume":"13","author":"Meesters-Ensing","year":"2022","journal-title":"Front Pharmacol"},{"issue":"14","key":"2026052611213877700_bib31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2026052611213877700_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100030","article-title":"Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation","volume":"1","author":"Dekker","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"1","key":"2026052611213877700_bib33","first-page":"122","article-title":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial","volume":"111","author":"Balduzzi","year":"2025","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3719\/2521702\/blooda_adv-2025-019142-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3719\/2521702\/blooda_adv-2025-019142-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:21:49Z","timestamp":1779808909000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3719\/566926\/Refining-busulfan-exposure-enhances-pediatric-ALL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019142","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,26]]}}}